These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 38974365)
21. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Zhang QQ; An X; Liu YH; Li SY; Zhong Q; Wang J; Hu HD; Zhang DZ; Ren H; Hu P Virol J; 2011 Feb; 8():72. PubMed ID: 21324130 [TBL] [Abstract][Full Text] [Related]
22. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Hosaka T; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H Aliment Pharmacol Ther; 2019 Feb; 49(4):457-471. PubMed ID: 30663078 [TBL] [Abstract][Full Text] [Related]
23. Older Age and High α-Fetoprotein Predict Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis-B-Related Cirrhotic Patients Receiving Long-Term Nucleos(t)ide Analogue Therapy. Liu YY; Lin CL; Weng CH; Chang PH; Chien CH; Huang KC; Hua MC; Hu CC Diagnostics (Basel); 2022 Aug; 12(9):. PubMed ID: 36140487 [TBL] [Abstract][Full Text] [Related]
24. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P JHEP Rep; 2021 Jun; 3(3):100290. PubMed ID: 34041470 [TBL] [Abstract][Full Text] [Related]
25. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B. Chun HS; Papatheodoridis GV; Lee M; Lee HA; Kim YH; Kim SH; Oh YS; Park SJ; Kim J; Lee HA; Kim HY; Kim TH; Yoon EL; Jun DW; Ahn SH; Sypsa V; Yurdaydin C; Lampertico P; Calleja JL; Janssen H; Dalekos GN; Goulis J; Berg T; Buti M; Kim SU; Kim YJ J Hepatol; 2024 Jan; 80(1):20-30. PubMed ID: 37734683 [TBL] [Abstract][Full Text] [Related]
26. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients. Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248 [TBL] [Abstract][Full Text] [Related]
27. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. Li J; Yang HI; Yeh ML; Le MH; Le AK; Yeo YH; Dai CY; Barnett S; Zhang JQ; Huang JF; Trinh HN; Wong C; Wong C; Hoang JK; Cheung R; Yu ML; Nguyen MH J Infect Dis; 2021 Jul; 224(2):294-302. PubMed ID: 33249474 [TBL] [Abstract][Full Text] [Related]
28. A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues. Gu Y; Zhang Y; Zhang Z; Wang J; Zhang Q; Zhang S; Liu Y; Liu J; Xia J; Yan X; Li J; Liu X; Huang R; Wu C Ann Hepatol; 2024; 29(1):101151. PubMed ID: 37704066 [TBL] [Abstract][Full Text] [Related]
29. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Hirode G; Choi HSJ; Chen CH; Su TH; Seto WK; Van Hees S; Papatheodoridi M; Lens S; Wong G; Brakenhoff SM; Chien RN; Feld J; Sonneveld MJ; Chan HLY; Forns X; Papatheodoridis GV; Vanwolleghem T; Yuen MF; Hsu YC; Kao JH; Cornberg M; Hansen BE; Jeng WJ; Janssen HLA; Gastroenterology; 2022 Mar; 162(3):757-771.e4. PubMed ID: 34762906 [TBL] [Abstract][Full Text] [Related]
30. High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy. Chang X; Li Y; Sun C; Li X; Du W; Shang Q; Song L; Long Q; Li Q; Liu H; Wang J; Yu Z; Li J; Xiao G; Li L; Chen L; Tan L; Chen Y; Yang Y J Gastroenterol; 2023 May; 58(5):481-493. PubMed ID: 36928343 [TBL] [Abstract][Full Text] [Related]
31. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948 [TBL] [Abstract][Full Text] [Related]
32. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B. Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870 [TBL] [Abstract][Full Text] [Related]
33. Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis. Zhu F; Zhang Q; Zhang Q; Zhang D Microb Pathog; 2020 Feb; 139():103912. PubMed ID: 31816402 [TBL] [Abstract][Full Text] [Related]
34. Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. Papatheodoridi M; Su TH; Hadziyannis E; Liao CH; Orfanidou Α; Yang HC; Zachou K; Liu CJ; Kourikou A; Gatselis N; Manolakopoulos S; Dalekos G; Kao JH; Hadziyannis S; Papatheodoridis GV Liver Int; 2022 Mar; 42(3):541-550. PubMed ID: 34890120 [TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. Choi WM; Yip TC; Wong GL; Kim WR; Yee LJ; Brooks-Rooney C; Curteis T; Cant H; Chen CH; Chen CY; Huang YH; Jin YJ; Jun DW; Kim JW; Park NH; Peng CY; Shin HP; Shin JW; Yang YH; Lim YS J Hepatol; 2023 Mar; 78(3):534-542. PubMed ID: 36572349 [TBL] [Abstract][Full Text] [Related]
36. Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance. Choi J; Yoo S; Lim YS Hepatology; 2021 Jun; 73(6):2155-2166. PubMed ID: 33131063 [TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B. Arnold E; Yuan Y; Iloeje U; Cook G Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822 [TBL] [Abstract][Full Text] [Related]
38. Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance. Kim S; Yoo S; Lee JI; Kim S; Chang HY; Kim D; Jeong SH; Lee KS; Lee HW Dig Dis Sci; 2022 Jan; 67(1):321-328. PubMed ID: 33517556 [TBL] [Abstract][Full Text] [Related]
39. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients. Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801 [TBL] [Abstract][Full Text] [Related]
40. Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients. Boyd A; Piroth L; Maylin S; Maynard-Muet M; Lebossé F; Bouix C; Lascoux-Combe C; Mahjoub N; Girard PM; Delaugerre C; Carrat F; Lacombe K; Miailhes P J Viral Hepat; 2016 Dec; 23(12):1017-1026. PubMed ID: 27486094 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]